Health Care
5 companies compared on the lines they each report. Only figures more than one of them discloses appear here — a line only one company prints would read as a gap rather than a difference in disclosure.
37 comparable lines
Latest reported figure and its year-over-year change. Periods differ between companies — each reports on its own fiscal calendar.
| Line | ABBV | BMY | LLY | MRK | PFE |
|---|---|---|---|---|---|
| Weighted-average diluted shares outstandingIncome statement | 1,772+0.0% · Q3 FY2026 | 2,047+0.3% · Q1 FY2026 | 898,002−0.6% · Q4 FY2025 | 2,478−0.8% · Q3 FY2026 | 5,751+0.6% · Q3 FY2026 |
| Diluted earnings per share attributable to AbbVie Inc.Income statement | $2.37+2270.0% · Q3 FY2026 | $1.05−2.8% · Q3 FY2026 | $7.22+16.3% · Q3 FY2026 | $2.04−12.1% · Q3 FY2026 | $0.56−9.7% · Q3 FY2026 |
| Adjusted diluted earnings per shareIncome statement | $3.82+105.4% · Q3 FY2026 | $1.35−17.2% · Q3 FY2026 | $7.48+6.6% · Q3 FY2026 | −$1.28−157.7% · Q1 FY2026 | $0.87+0.0% · Q3 FY2026 |
| Net earningsIncome statement | $4.22bn+2144.7% · Q3 FY2026 | $2.68bn+8.8% · Q1 FY2026 | $6.45bn+15.5% · Q3 FY2026 | $5.07bn−12.4% · Q3 FY2026 | $3.24bn−8.4% · Q3 FY2026 |
| Net revenuesIncome statement | $17.4bn+10.3% · Q3 FY2026 | $13.07bn+6.9% · Q3 FY2026 | $24.4bn+38.6% · Q3 FY2026 | $18.09bn+4.7% · Q3 FY2026 | $16.58bn−0.4% · Q3 FY2026 |
| Effective tax rateMargins | — | 14.8%−49.8% · Q3 FY2026 | 23.3%+2.2% · Q3 FY2026 | 8.9%−37.3% · Q3 FY2026 | 3.9%+160.0% · Q3 FY2026 |
| Effective tax rate (Non-GAAP)Margins | — | 14.1%−36.8% · Q3 FY2026 | 24.0%+35.6% · Q3 FY2026 | 10.9%— · Q3 FY2026 | 14.0%+77.2% · Q3 FY2026 |
| Gross margin ratioMargins | 75.4%— · Q3 FY2026 | 68.3%−5.0% · Q3 FY2026 | $20.46bn+40.2% · Q3 FY2026 | 72.9%−6.2% · Q3 FY2026 | — |
| Adjusted gross margin ratioMargins | 85.1%— · Q3 FY2026 | 68.4%−6.2% · Q3 FY2026 | $20.59bn+40.0% · Q3 FY2026 | 81.4%−0.6% · Q3 FY2026 | — |
| As adjusted (non-GAAP) after-tax earningsIncome statement | $6.8bn+105.5% · Q3 FY2026 | — | $6.68bn+5.8% · Q3 FY2026 | $6.16bn−4.5% · Q3 FY2026 | $4.99bn+0.7% · Q3 FY2026 |
| Earnings before income tax expenseIncome statement | $4.83bn+576.3% · Q3 FY2026 | $2.54bn−18.6% · Q3 FY2026 | — | −$683m−113.7% · Q2 FY2026 | $3.39bn+1.5% · Q3 FY2026 |
| Research and developmentIncome statement | $2.57bn+10.7% · Q3 FY2026 | $2.37bn−6.4% · Q3 FY2026 | — | $4.54bn+7.2% · Q3 FY2026 | $3.02bn+18.5% · Q3 FY2026 |
| As adjusted (non-GAAP) R&DIncome statement | $2.43bn+7.5% · Q3 FY2026 | $2.36bn−2.8% · Q3 FY2026 | — | $4.53bn+13.4% · Q3 FY2026 | $2.94bn+18.3% · Q3 FY2026 |
| Selling, general and administrativeIncome statement | $4.09bn+14.5% · Q3 FY2026 | $1.7bn−5.0% · Q3 FY2026 | — | $2.89bn+9.6% · Q3 FY2026 | $3.28bn+2.9% · Q3 FY2026 |
| As adjusted (non-GAAP) SG&AIncome statement | $3.69bn+8.1% · Q3 FY2026 | $1.7bn−5.0% · Q3 FY2026 | — | $2.86bn+10.1% · Q3 FY2026 | $3.22bn+2.0% · Q3 FY2026 |
| Cost of salesIncome statement | — | — | $3.93bn+30.8% · Q3 FY2026 | $4.89bn+26.9% · Q3 FY2026 | $4.03bn−3.5% · Q3 FY2026 |
| Income tax provisionIncome statement | — | $374m−59.3% · Q3 FY2026 | — | $492m−48.6% · Q3 FY2026 | $134m+162.0% · Q3 FY2026 |
| As adjusted (non-GAAP) pre-tax earningsIncome statement | $7.87bn+79.6% · Q3 FY2026 | $3.22bn−24.4% · Q3 FY2026 | — | $550m— · Q2 FY2026 | — |
| Total Revenues - U.S.Segments | — | $9.07bn+8.9% · Q3 FY2026 | $15.1bn— · Q3 FY2026 | — | $10.6bn−0.8% · Q3 FY2026 |
| Acquired IPRDIncome statement | — | $1.56bn+146.1% · Q3 FY2026 | $4.18bn+537.3% · Q3 FY2026 | — | — |
| Cost of products soldIncome statement | $4.29bn−19.2% · Q3 FY2026 | $4.15bn+20.7% · Q3 FY2026 | — | — | — |
| As adjusted (non-GAAP) cost of products soldIncome statement | $2.6bn+2.1% · Q3 FY2026 | $4.13bn+24.8% · Q3 FY2026 | — | — | — |
| Non-GAAP Cost of salesIncome statement | — | — | — | $3.36bn+7.4% · Q3 FY2026 | $3.84bn−3.4% · Q3 FY2026 |
| EliquisSegments | — | $4.69bn+25.2% · Q3 FY2026 | — | — | $2.52bn+25.2% · Q3 FY2026 |
| Income before income taxesIncome statement | — | — | $8.27bn+64.0% · Q4 FY2025 | $5.56bn−17.6% · Q3 FY2026 | — |
| Income tax expenseIncome statement | $609m+15.8% · Q3 FY2026 | — | $1.96bn+18.5% · Q3 FY2026 | — | — |
| Income tax provision (Non-GAAP)Income statement | — | $723m+10.9% · Q1 FY2026 | — | $882m— · Q2 FY2026 | — |
| Total Revenues - Int'lSegments | — | $4bn+2.6% · Q3 FY2026 | — | — | $5.98bn+0.3% · Q3 FY2026 |
| Net earnings attributable to AbbVie Inc.Income statement | $4.22bn+2167.7% · Q3 FY2026 | $2.16bn−1.8% · Q3 FY2026 | — | — | — |
| OncologySegments | $1,696bn— · Q3 FY2026 | — | — | — | $4.33bn+9.9% · Q3 FY2026 |
| Operating earningsIncome statement | $6.27bn+229.1% · Q3 FY2026 | — | $8.61bn+16.9% · Q3 FY2026 | — | — |
| Operating margin ratioMargins | 36.0%— · Q3 FY2026 | 29.1%+63.5% · Q4 FY2025 | — | — | — |
| Adjusted operating margin ratioMargins | 48.7%— · Q3 FY2026 | 34.8%+1.5% · Q4 FY2025 | — | — | — |
| Other (income)/expense, netIncome statement | — | $307m+384.3% · Q3 FY2026 | — | $27m+111.3% · Q3 FY2026 | — |
| Other (income)/expense, net (Non-GAAP)Income statement | — | $93m+145.1% · Q3 FY2026 | — | $420m+296.2% · Q3 FY2026 | — |
| Research and developmentIncome statement | — | $2.59bn−19.0% · Q4 FY2025 | $4.25bn+22.5% · Q3 FY2026 | — | — |
| Net revenues U.S.Segments | $12.86bn— · Q2 FY2026 | — | $14.4bn— · Q2 FY2026 | — | — |
Data from company filings. Not investment advice.